Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 98

Sort by

Sort Order Select

Journal Articles

Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients ≤ 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181

Nina Wagner-Johnston, Opeyemi Jegede, Stephen E Spurgeon, Kami J. Maddocks, David T Yang, Justin Romanoff, Jonas Paludo, Paolo F. Caimi, Nancy L. Bartlett, Patrick M. Reagan, Yazeed Sawalha, Marc Hoffmann, Boyu Hu, Ashraf R Aziz, Helga Marques, Lale Kosakoglu Shields, John P. Leonard, Jonathan W. Friedberg, Brad S. Kahl

Blood (2024) 144 (Supplement 1): 236.

https://doi.org/10.1182/blood-2024-194641

Published: 2024

Journal Articles

BP43131, a Phase 1 Dose Escalation Study: CD19 Targeted CD28 Costimulatory Agonist (RO7443904) Combined with Glofitamab Shows Promising Efficacy in Patients with Relapsed/Refractory Aggressive B-NHL

Blood (2024) 144 (Supplement 1): 3123.

https://doi.org/10.1182/blood-2024-205544

Published: 2024

Journal Articles

CD19-CD28 (RO7443904) Combination with Glofitamab Enhances T-Cell Proliferation and Effector Function in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)

Blood (2024) 144 (Supplement 1): 644.

https://doi.org/10.1182/blood-2024-201406

Published: 2024

Journal Articles

Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study

Blood (2024) 144 (Supplement 1): 111.

https://doi.org/10.1182/blood-2024-199330

Published: 2024

Journal Articles

A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001) and Orthogonal IL-2 (STK-009) in Subjects with Relapsed or Refractory CD19 Expressing Hematologic Malignancies (NCT05665062)

Maria Lia Palomba, Paolo F. Caimi, Matthew Mei, Francisco Hernandez-Ilizaliturri, Geoffrey Shouse, Allison M. Winter, Greg Yedinak, David Mou, Nestor Huang, Anna Moua, Martin Oft, Paul-Joseph Aspuria, Anita Mehta-Damani, Naiyer Rizvi, Sherry Unabia, Peg Taylor, Jeffrey McLeroy, Matthew J Cortese

Blood (2024) 144 (Supplement 1): 3453.

https://doi.org/10.1182/blood-2024-202090

Published: 2024

Journal Articles

Outcomes of Waldenström Macroglobulinemia Patients Requiring Therapeutic Plasma Exchange. Higher Rates of Progression and Resistance of Initial Systemic Therapy

Jessica Leng, Jack Khouri, Allison M. Winter, Deepa Jagadeesh, Robert M. Dean, Taylor R. Brooks, Louis Williams, Faiz Anwer, Craig S. Sauter, Brian T. Hill, Paolo F. Caimi

Blood (2024) 144 (Supplement 1): 6342.

https://doi.org/10.1182/blood-2024-206344

Published: 2024

Journal Articles

Phase 1 Study of ARV-393, a PROTAC BCL6 Degrader, in Advanced Non-Hodgkin Lymphoma

Paolo F. Caimi, Scott F Huntington, Sean Landrette, Sheryl M Gough, Vivian Dai, Bryan Jackson, Tinghui Yu, Juan Chavez, Sarah Tannenbaum-Dvir, Matthew Matasar

Blood (2024) 144 (Supplement 1): 6505.

https://doi.org/10.1182/blood-2024-208356

Published: 2024

Journal Articles

Phase I Study Results of UF-Kure19, a CAR-T Product Manufactured in Less Than 1 Day, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma

Changchun Deng, Paolo F. Caimi, Umar Farooq, Nethrie Idippily, Maria Florencia Giraudo, Jane S. Reese, Sarah Kleinsorge-Block, Daniel Caley, Ryan Stadel, Koen van Besien, Marcos de Lima, Arun Kumar Arunachalam, J. Joseph Melenhorst, David Wald

Blood (2024) 144 (Supplement 1): 94.

https://doi.org/10.1182/blood-2024-206596

Published: 2024

Journal Articles

Glofitamab in Combination with Rituximab Plus Ifosfamide, Carboplatin, and Etoposide Shows Favorable Efficacy and Manageable Safety in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Eligible for Stem Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: Results from a Phase Ib Study

Catherine S. Diefenbach, Paolo F. Caimi, Nakhle S Saba, Fernando Vargas Madueno, Mehdi Hamadani, Luis E. Fayad, Peter A. Riedell, Andrew Gillis-Smith, Stephen Simko, Victor Orellana-Noia, Maria Filippou-Frye, Amy V. Kapp, James Relf, Linda Lundberg, Lauren C. Pinter-Brown

Blood (2024) 144 (Supplement 1): 987.

https://doi.org/10.1182/blood-2024-198452

Published: 2024

Journal Articles

Clinical Outcomes of Lymphoplasmacytic Lymphoma / Waldenstrom Macroglobulinemia (LPL/WM) in the Targeted Therapy Era: A US Multicenter Retrospective Analysis

Blood (2024) 144 (Supplement 1): 4392.

https://doi.org/10.1182/blood-2024-199278

Published: 2024

Journal Articles

Real World Experience with Time Limited Venetoclax and Obinutuzumab (VO) for Frontline Treatment of CLL/SLL with MRD Determination By Clonoseq®

Allison M. Winter, Olivia Landever, Hiruni Mendries, Willem Van Heeckeren, Chieh-Lin Fu, Robert M. Dean, Taylor R. Brooks, Deepa Jagadeesh, Paolo F. Caimi, Brian T. Hill

Blood (2024) 144 (Supplement 1): 3247.

https://doi.org/10.1182/blood-2024-200306

Published: 2024

Journal Articles

Loncastuximab Tesirine in Combination with Venetoclax Is Safe and Shows Efficacy in Patients with Relapsed/Refractory Non Hodgkin Lymphoma

Paolo F. Caimi, Allison M. Winter, Robert M. Dean, Taylor R. Brooks, Deepa Jagadeesh, Craig S. Sauter, Brian T. Hill

Blood (2024) 144 (Supplement 1): 4499.

https://doi.org/10.1182/blood-2024-202154

Published: 2024

Journal Articles

Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL

Blood (2024) 144 (10): 1083–1092.

https://doi.org/10.1182/blood.2024023962

Published: 2024

Includes: Supplemental data

Journal Articles

Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study

Blood (2023) 142 (26): 2327–2331.

https://doi.org/10.1182/blood.2023021274

Published: 2023

Includes: Supplemental data

Journal Articles

A Phase I Clinical Trial of Fully Human Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

Brenda W Cooper, Molly Megan Gallogly, Leland Metheny, Rebecca B. Klisovic, Kirsten Marie Boughan, Jane Reese Koc, Darong Wu, Changchun Deng, Koen Van Besien, Rose Tupta, Dina Schneider, Lisa Ciarrone, Marcos de Lima, Paolo F. Caimi, Benjamin K. Tomlinson

Blood (2023) 142 (Supplement 1): 6872.

https://doi.org/10.1182/blood-2023-191153

Published: 2023

Journal Articles

Improved Survival of R/R Double Hit/Triple Hit Lymphoma in the Era of CD19 Chimeric Antigen T Cell (CART) Therapy

Blood (2023) 142 (Supplement 1): 308.

https://doi.org/10.1182/blood-2023-183001

Published: 2023

Journal Articles

Final Results of a Phase I/II Trial of Carfilzomib + R-CHOP for Frontline Treatment of Patients with Non-Germinal Center Diffuse Large B-Cell Lymphoma (DLBCL)

Brian T. Hill, Pallawi Torka, Francisco J. Hernandez-Ilizaliturri, Robert M. Dean, Deepa Jagadeesh, Kasra Karamlou, Chieh-Lin Fu, Allison Winter, Ethan Krauspe, Jonathan Zhou, Taylor R. Brooks, Merve Kacar, Ben K. Tomlinson, Brenda W Cooper, Hong Li, Xuefei Jia, Yanwen Chen, Jenna Thomas, Paolo F. Caimi

Blood (2023) 142 (Supplement 1): 3087.

https://doi.org/10.1182/blood-2023-173943

Published: 2023

Journal Articles

The Relapse-to-Therapy Interval in Relapsed or Refractory Diffuse Large B Cell Lymphoma Is Associated with Clinical Outcomes

Paolo F. Caimi, Christine Auberle, Krishna Goparaju, Molly Megan Gallogly, Firas Baidoun, Amanda F Cashen, Brian T. Hill

Blood (2023) 142 (Supplement 1): 1766.

https://doi.org/10.1182/blood-2023-181274

Published: 2023

Journal Articles

Efficacy and Safety of a Third Generation CD20 CAR-T (MB-106) for Treatment of Relapsed/Refractory Indolent B-Cell Non-Hodgkin Lymphoma: Phase-1 Results from a Multicenter Trial

Mazyar Shadman, Paolo F. Caimi, Susan M. O'Brien, Patrick M. Reagan, Bruce Dezube, Punya Navaratnarajah, Tripti Gaur, Suzanne Petrossian, Anthony Germani, Brian G Till, Jeremy S. Abramson

Blood (2023) 142 (Supplement 1): 2102.

https://doi.org/10.1182/blood-2023-175007

Published: 2023

Journal Articles

Outcomes of Lymphoma and Multiple Myeloma Patients Following Inpatient Antineoplastic Treatment

Blood (2023) 142 (Supplement 1): 7245.

https://doi.org/10.1182/blood-2023-190304

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients ≤ 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181

BP43131, a Phase 1 Dose Escalation Study: CD19 Targeted CD28 Costimulatory Agonist (RO7443904) Combined with Glofitamab Shows Promising Efficacy in Patients with Relapsed/Refractory Aggressive B-NHL

CD19-CD28 (RO7443904) Combination with Glofitamab Enhances T-Cell Proliferation and Effector Function in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)

Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study

A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001) and Orthogonal IL-2 (STK-009) in Subjects with Relapsed or Refractory CD19 Expressing Hematologic Malignancies (NCT05665062)

Outcomes of Waldenström Macroglobulinemia Patients Requiring Therapeutic Plasma Exchange. Higher Rates of Progression and Resistance of Initial Systemic Therapy

Phase 1 Study of ARV-393, a PROTAC BCL6 Degrader, in Advanced Non-Hodgkin Lymphoma

Phase I Study Results of UF-Kure19, a CAR-T Product Manufactured in Less Than 1 Day, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma

Clinical Outcomes of Lymphoplasmacytic Lymphoma / Waldenstrom Macroglobulinemia (LPL/WM) in the Targeted Therapy Era: A US Multicenter Retrospective Analysis

Real World Experience with Time Limited Venetoclax and Obinutuzumab (VO) for Frontline Treatment of CLL/SLL with MRD Determination By Clonoseq®

Loncastuximab Tesirine in Combination with Venetoclax Is Safe and Shows Efficacy in Patients with Relapsed/Refractory Non Hodgkin Lymphoma

Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL

Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study

A Phase I Clinical Trial of Fully Human Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

Improved Survival of R/R Double Hit/Triple Hit Lymphoma in the Era of CD19 Chimeric Antigen T Cell (CART) Therapy

Final Results of a Phase I/II Trial of Carfilzomib + R-CHOP for Frontline Treatment of Patients with Non-Germinal Center Diffuse Large B-Cell Lymphoma (DLBCL)

The Relapse-to-Therapy Interval in Relapsed or Refractory Diffuse Large B Cell Lymphoma Is Associated with Clinical Outcomes

Efficacy and Safety of a Third Generation CD20 CAR-T (MB-106) for Treatment of Relapsed/Refractory Indolent B-Cell Non-Hodgkin Lymphoma: Phase-1 Results from a Multicenter Trial

Outcomes of Lymphoma and Multiple Myeloma Patients Following Inpatient Antineoplastic Treatment

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only